Press Release - Vertex Pharmaceuticals Newsroom
2024年3月21日 · BOSTON--(BUSINESS WIRE)--Mar. 21, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant ...
Press Release - Vertex Pharmaceuticals Newsroom
2024年4月10日 · Under the terms of the merger agreement, Vertex will acquire Alpine for $65 per share in cash, for a total equity value of approximately $4.9 billion, or approximately $4.6 billion net of estimated cash acquired. A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
Press Release - Vertex Pharmaceuticals Newsroom
2024年1月30日 · Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain – Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and bunionectomy randomized ...
Vertex Reports Third Quarter 2024 Financial Results | Vertex ...
2024年9月30日 · BOSTON--(BUSINESS WIRE)--Nov. 4, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to …
Press Release - Vertex Pharmaceuticals Newsroom
2024年4月9日 · BOSTON--(BUSINESS WIRE)--Apr. 9, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a …
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of ...
2024年9月26日 · BOSTON--(BUSINESS WIRE)--Sep. 26, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor (“vanza triple”) — the potential next-in-class triple combination medicine — will take place at ...
Press Release - Vertex Pharmaceuticals Newsroom
2024年4月23日 · TreeFrog and Vertex will collaborate to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s T1D therapies. TreeFrog’s proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to …
Press Release - Vertex Pharmaceuticals Newsroom
2024年7月30日 · Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain – FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 –
Vertex to Announce First Quarter 2023 Financial Results on May 1 ...
2023年4月10日 · BOSTON--(BUSINESS WIRE)--Apr. 10, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close. The company will host a …
Press Release - Vertex Pharmaceuticals Newsroom
2024年2月23日 · LONDON--(BUSINESS WIRE)--Feb. 23, 2024-- Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KALYDECO ® (ivacaftor) for the treatment of infants with cystic fibrosis (CF) ages 1 month to ...